What is irinotecan sucrosofate?
Irinotecan sucrosofate is a drug form of irinotecan (a chemotherapy agent) that is delivered as an irinotecan–sucrose ester complex. This formulation is designed to change how the drug is released and handled in the body compared with standard irinotecan products.
How does it differ from standard irinotecan?
The key practical difference is formulation. Standard irinotecan is marketed as a separate drug product, while irinotecan sucrosofate is a different salt/complex/formulation intended to affect drug delivery and metabolism. That can matter for how the drug is dosed, administered, and how patients experience side effects, but the active chemotherapy agent is still irinotecan.
What is it used for?
Irinotecan-based chemotherapy regimens are commonly used in cancers such as colorectal cancer (often in combination or second-line settings). Specific approved indications depend on the country and the particular approved product containing irinotecan sucrosofate.
What side effects are typical for irinotecan-based treatment?
Side effects associated with irinotecan generally include diarrhea and low white blood cell counts (neutropenia), among other chemotherapy-related effects. Because irinotecan sucrosofate is still irinotecan-based chemotherapy, patients should expect a similar side-effect profile, though the formulation can influence timing and intensity in some cases.
Is this related to patents or market exclusivity?
Patent status and exclusivity depend on the specific irinotecan sucrosofate product, manufacturer, and jurisdiction. If you want, share the country or the brand/manufacturer name you’re researching, and I can help check patent/exclusivity information using DrugPatentWatch.com.
What should you ask your oncologist if you’re considering this regimen?
Patients often want to know: the exact dosing schedule, how diarrhea prevention is handled, whether there are special precautions for infection or low blood counts, and whether there are alternatives using standard irinotecan or other drug classes.
---
If you tell me the brand name (or the country you’re in) for “irinotecan sucrosofate,” I can give more specific answers on approved indications, dosing, and any patent/exclusivity details.